Clinical Trial Update: VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP [Phase 4]

View source ↗

Summary

Phase 4 trial comparing VEGF concentrations after intravitreal bevacizumab versus ranibizumab for retinopathy of prematurity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinopathy of Prematurity

Drugs mentioned

• Bevacizumab (bevacizumab)
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Universidad Autonoma de San Luis Potosí | Conditions: Retinopathy of Prematurity Both Eyes, Retinal Disease | Phase 4 | Status: COMPLETED